TICKERNERD
Menu
IRDIRDHealthcare · Biotechnology

IRD Stock Forecast: Opus Genetics, Inc. Price Predictions for 2026-2027

Last close, 8 Sept 2026
$4.34
−7.07% on the day

The 18 Wall Street analysts covering Opus Genetics, Inc. hold a median 12-month price target of $10 — +130.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 51 of 100 as at 8 Sept 2026 — in the upper half.

Market cap
$388.5M
Ticker Nerd rank
51 / 100
Median analyst target
$10
Analysts covering
18
Revenue$755K−73.8% y/y
Operating income−$16.5M
Net income−$8.1M
Free cash flow−$11.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+19.9%
1M
+18.6%
YTD
+115.9%
1Y
+210.0%
From 52W high
−24.5%
From 52W low
+226.3%
$1.33
$5.75
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

IRD stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Opus Genetics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Sept 2026
51 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
93
Growth
67
Accruals
66
Size
59
Revisions
57
Value
53
Volatility
51
Quality
19
Issuance
5

Momentum (93): The shares have been drifting up relative to others.

Issuance (5): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

IRD stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on IRD, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00Oct 25Jan 26Apr 26Jul 26IRDHigh $16Median $10Low $8

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says18 analysts
18 Buy0 Hold0 Sell
Low $8Median $10High $16

The green dot is the last close — the median target sits +130.4% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
7 Aug 2026RBC CapitalMaintainsOutperform$10 → $9.00
29 July 2026TD CowenInitiatesBuy—
29 July 2026TD CowenInitiatesBuy—
6 July 2026BTIGReiteratesBuy—
6 July 2026BTIGReiteratesBuy$12
6 July 2026Chardan CapitalMaintainsBuy—
6 July 2026Chardan CapitalMaintainsBuy$13
18 June 2026Chardan CapitalMaintainsBuy—
17 June 2026HC Wainwright & Co.ReiteratesBuy—
16 June 2026BTIGReiteratesBuy—
15 June 2026CitizensReiteratesMarket Outperform—
4 June 2026GuggenheimInitiatesBuy—
21 May 2026Leerink PartnersInitiatesOutperform—
13 May 2026CitizensMaintainsMarket Outperform—
28 Apr 2026CitizensInitiatesMarket Outperform—
30 Mar 2026Cantor FitzgeraldInitiatesOverweight—
16 Mar 2026OppenheimerInitiatesOutperform—
12 Mar 2026Chardan CapitalMaintainsBuy—
12 Mar 2026WedbushMaintainsOutperform—
2 Mar 2026BTIGMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. IRD appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

IRD vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Sept 2026, Opus Genetics, Inc. returned +210.0% against +19.4% for the S&P 500, dividends included.

IRD vs S&P 500, last 12 monthsTotal return, rebased to 100
100200300400Oct 25Jan 26Apr 26Jul 26IRDS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

IRD analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
7
Analysts cutting
2
Fundamentals

Opus Genetics, Inc. (IRD) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−5.8×

Cheaper than 90% of US stocks

Price / sales
39.4×

Cheaper than 6% of US stocks

Price / book
−34.2×

Cheaper than 99% of US stocks

EV / EBITDA
−6.6×

Cheaper than 81% of US stocks

Growth & margins
Revenue growth (YoY)
−73.8%

Higher than 3% of US stocks

Earnings growth (YoY)
−73.8%

Higher than 6% of US stocks

Gross margin
—
Operating margin
−2182.8%

Higher than 4% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−4796.5%

Higher than 1% of US stocks

Return on assets
−48.1%

Higher than 8% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Opus Genetics, Inc. (IRD) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Opus Genetics, Inc. has a market value of $388.5M and an enterprise value of $335.9M.

  • Revenue in the twelve months to 30 June 2026: $9.9M. The latest quarter shrank 73.8% year on year.

  • Net income over the same four quarters: −$107.6M, a −1091.8% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$40.7M.

  • Opus Genetics, Inc. spent $149K on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 82.6M.

  • Trailing P/E: −5.8×; forward P/E: −6.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Opus Genetics, Inc. employs 27 people — $365K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 8 Sept 2026

Data provided by Twelve Data

Peers

IRD vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
IRDOpus Genetics, Inc.$388.5M
51
DMACDiaMedica Therapeutics, Inc.$352.7M
45
QTTBQ32 Bio, Inc.$347.9M
83
XFORX4 Pharmaceuticals, Inc.$347.5M
62
IKTInhibikase Therapeutics, Inc.$339.1M
33
UPBUpstream Bio, Inc.$339.0M
28
IPSCCentury Therapeutics, Inc.$371.9M
38

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Opus Genetics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest IRD news & analysis

Opus Genetics Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of OPGx-BEST1 and Successful FDA Type C Meeting with Potential Phase 3 Dosing in 2027

GlobeNewsWire · 9 Sept 2026positive

Opus Genetics announced positive low-dose Cohort 1 data from its Phase 1/2 trial of OPGx-BEST1, showing a favorable safety and tolerability profile with no serious adverse events and clinically meaningful improvements in visual function for all five participants. The company also completed a successful FDA Type C meeting aligning on a potential pivotal endpoint, with potential Phase 3 dosing in 2027 and cash runway into 2029.

Why it matters — The encouraging early safety and efficacy data, plus FDA alignment on a pivotal endpoint, could advance this gene therapy candidate toward later-stage trials for BEST1-related inherited retinal disease.

Opus Genetics to Present OPGx-BEST1 Cohort 1 Clinical Data in Investor Webcast and at Upcoming Leading Ophthalmology Conferences

GlobeNewsWire · 2 Sept 2026positive

Opus Genetics will present topline data from Phase 1/2 Cohort 1 of its OPGx-BEST1 gene therapy program during an investor webcast on September 9 at 8:00 a.m. ET. The full clinical dataset and additional analyses of visual function measures will also be presented at upcoming ophthalmology conferences.

Why it matters — This represents the first disclosure of clinical data for OPGx-BEST1, a gene therapy targeting BEST1-related inherited retinal disease, which IRD watchers closely follow for potential therapeutic progress.

Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 19 Aug 2026neutral

Opus Genetics announced that the Compensation Committee of its Board of Directors approved equity awards under the company's 2021 Inducement Plan as material inducements to employment for three non-executive employees who were not previously employees or directors of the company. The grants were made under Nasdaq Listing Rule 5635(c)(4).

Why it matters — For IRD watchers, the inducement grants signal the company's hiring of new talent to support its clinical-stage gene therapy programs for inherited retinal diseases.

Opus Genetics, Inc. (IRD) Reports Q2 Loss, Lags Revenue Estimates

Zacks Investment Research · 6 Aug 2026negative

Opus Genetics, Inc. (IRD) reported a quarterly loss of $0.14 per share, narrower than the Zacks Consensus Estimate of a $0.15 loss but wider than the $0.12 loss a year ago. The company's revenue lagged estimates for the quarter.

Why it matters — IRD watchers would care because the Q2 result beat analyst expectations on the bottom line, though the widening year-over-year loss and revenue shortfall point to ongoing pressure on the company's financials.

Opus Genetics Announces Financial Results for Second Quarter 2026 and Provides Corporate Update

GlobeNewsWire · 6 Aug 2026neutral

Opus Genetics, Inc. announced its financial results for the second quarter of 2026 and provided a corporate update. Based on the item provided, the announcement reports the company's quarterly financial performance and an update on its activities.

Why it matters — For watchers of this inherited retinal disease (IRD) company, the corporate update often accompanies the financial results with information about the progress of its programs.

FAQ

Frequently asked questions about IRD stock

What is the IRD stock price forecast for 2026-2027?

The 18 Wall Street analysts covering Opus Genetics, Inc. have a median 12-month price target of $10, with estimates ranging from $8 to $16. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is IRD stock a buy right now?

Of the 18 analysts covering Opus Genetics, Inc., 18 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Opus Genetics, Inc. 51 out of 100 across roughly 4,600 US stocks as at 8 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank IRD?

As at 8 Sept 2026, Opus Genetics, Inc. ranks 51 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (93 of 100).

Will IRD stock go up?

No one can know that. What the data says: the median 12-month target from 18 analysts implies +130.4% from the last close, and Ticker Nerd's factor model ranks Opus Genetics, Inc. 51 out of 100 as at 8 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the IRD stock forecast for 2030?

No analyst covering Opus Genetics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IRD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $16 over the next 12 months.

How has IRD stock performed over the past year?

Opus Genetics, Inc. returned +210.0% over the 12 months to 8 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Opus Genetics, Inc. do?

Opus Genetics, Inc. Common Stock represents an equity interest in Opus Genetics, a clinical-stage biopharmaceutical company focused on ophthalmic therapies.

What is the latest news on IRD?

The most recent item we track (GlobeNewsWire, 9 Sept 2026): "Opus Genetics Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of OPGx-BEST1 and Successful FDA Type C Meeting with Potential Phase 3 Dosing in 2027". Opus Genetics announced positive low-dose Cohort 1 data from its Phase 1/2 trial of OPGx-BEST1, showing a favorable safety and tolerability profile with no serious adverse events and clinically meaningful improvements in visual function for all five participants. The company also completed a successful FDA Type C meeting aligning on a potential pivotal endpoint, with potential Phase 3 dosing in 2027 and cash runway into 2029.

Company

About Opus Genetics, Inc.

Opus Genetics, Inc. Common Stock represents an equity interest in Opus Genetics, a clinical-stage biopharmaceutical company focused on ophthalmic therapies. The company develops gene therapies for inherited retinal diseases and additional small-molecule treatments for other eye disorders, including programs aimed at retinal degeneration, refractive conditions, and other vision-related diseases. Its current pipeline includes investigational candidates such as OPGx-LCA5 and OPGx-BEST1, along with other ophthalmology-focused programs targeting specific genetic retinal conditions. Opus Genetics serves the broader vision-care market through research, development, and commercialization efforts centered on restoring or preserving sight in patients with unmet medical needs. The company is headquartered in Durham, North Carolina.

CEO Dr. George Magrath M.B.A., M.D., M.S. · 27 employees · United States · https://opusgtx.com